	US 12,263,221 B2
	Chimeric antigen receptor comprising BCMA nanobody linked to a chimeric intracellular signaling domain
William A. Comrie, Silver Spring, MD (US); and Wenshan Hao, Parsippany, NJ (US)
Assigned to Neomics Pharmaceuticals LLC, Rockville, MD (US)
Filed by Neomics Pharmaceuticals LLC, Gaithersburg, MD (US)
Filed on Jul. 5, 2023, as Appl. No. 18/347,487.
Claims priority of provisional application 63/358,399, filed on Jul. 5, 2022.
Prior Publication US 2024/0009309 A1, Jan. 11, 2024
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 15/62 (2006.01)

CPC A61K 39/464417 (2023.05) [A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2878 (2013.01); C12N 15/62 (2013.01); A61K 2239/13 (2023.05); A61K 2239/22 (2023.05); A61K 2239/48 (2023.05); C07K 2317/569 (2013.01); C07K 2319/33 (2013.01)]

7 Claims

1. A chimeric antigen receptor that binds B cell maturation antigen (BCMA-CAR), comprising:

(a) an extracellular domain comprising the amino acid sequence of SEQ ID NO: 8;

(b) a transmembrane domain; and

(c) a chimeric intracellular domain comprising a first, a second and at least a third signal transduction domain, wherein

the first signal transduction domain consists of an ICOS intracellular domain as set forth in SEQ ID NO: 2,

the second signal transduction domain consists of a truncated CD137 (4-1BB) intracellular domain as set forth in SEQ ID NO: 3, and

the at least third signal transduction domain consists of a truncated CD3ζ domain as set forth in SEQ ID NO: 4,

wherein the BCMA-CAR comprises the amino acid sequence as set forth in SEQ ID NO: 5.